ClinicalTrials.gg
RecruitingNCT06337292iVACUpdated May 12, 2026

Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures

A Phase 3 interventional study of Incisional Negative Pressure Wound Therapy (NPWT) in Fracture of Tibia, Wound Heal and Infected Wound, sponsored by Major Extremity Trauma Research Consortium. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Major Extremity Trauma Research Consortium · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Tibial Fractures with a site in United States — 15 open to participants now, 18 under way, 3 of them phase 3. Tibial Fractures · United States.

Planned enrollment
6th of 38
352 · median 53
Started
2025
with 3 others
Phase 3
4 of 50
2 open now
Primary completion
2028-09
later than 15 of 17 live
Registered
43rd of 50
by date
Lead sponsor
3 of 50
Major Extremity Trauma Research Consortium

Among the 50 studies in Tibial Fractures with a site in United States, this one is the 6th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 15 of the 17 other live ones, and was the 43rd registered.

Tibial Fractures

136 studies on the registry are indexed under Tibial Fractures; 38 are open to participants now.

Browse Tibial Fractures studies →

Open to participants now

15 of the 50 studies in Tibial Fractures with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Tibial Fractures studies recruiting now, 13 (48%) set no upper age limit and 7 (26%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Tibial Fractures with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, pragmatic, parallel arm randomized controlled trial (RCT) of 352 patients with high-risk open or closed tibial plateau fracture, high-risk open or closed tibial pilon fracture, or open tibial shaft fracture with incision >3cm. Eligible participants will be randomized to receive either incisional negative pressure wound therapy (NPWT) or a non-suction standard-of-care wound dressing for their definitive wound management. The primary outcome will be a composite outcome to evaluate clinical status 3 months after randomization.

03

Conditions studied

  • Fracture of Tibia
  • Wound Heal
  • Infected Wound
  • Wound Complication
  • Wound Dehiscence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All open or closed tibial plateau or pilon fractures treated operatively with internal fixation at high risk for complication. Any open Gustilo Type I, II or IIIA tibial shaft fracture treated definitively with internal or external fixation with or without ipsilateral leg compartment syndrome if at least one wound is primarily closed.
  2. We define high-risk fractures as those that are either:

    • Closed fracture initially treated with an external fixator (with or without limited internal fixation) and treated definitive more than 3 days later after swelling has resolved;
    • Any open type I, II or IIIA fracture, regardless of timing of definitive treatment;
    • Any tibial plateau fracture associated with ipsilateral leg compartment syndrome fasciotomy wounds that has at least one wound primarily closed
  3. Requiring incision for fixation or debridement of 3 cm or greater.
  4. Patients 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  1. The study injury is already infected at time of study enrollment.
  2. Patient is unable to receive incisional NPWT for any reason.
  3. Patients who have already had definitive fixation prior to enrollment in the study.
  4. Severe problems with maintaining follow-up (e.g., patients who are homeless at the time of injury or those who are intellectually challenged without adequate family support or who are prisoners).
  5. The study injury is a Gustilo Type IIIB or IIIC open fracture.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
352 participants (estimated)

Study arms

  • No intervention
    Standard of Care Wound Care

    Patients randomized to the control group will receive standard wound care.

  • Experimental
    Incisional Negative Pressure Wound Therapy (NPWT)

    Patients randomized to the treatment group will receive wound care which includes the application of an incisional negative pressure wound vacuum.

    Device: Incisional Negative Pressure Wound Therapy (NPWT)

Interventions

  • DeviceIncisional Negative Pressure Wound Therapy (NPWT)

    Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.

06

What researchers measure

Primary outcomes

  1. Complication composite outcome

    The primary outcome will be a composite outcome. We will hierarchically assess the components of the composite outcome in the following order: (1) all-cause mortality, (2) injury-related amputation of the lower extremity, (3) number of surgeries to treat a deep or organ space infection (CDC criteria), (4) wound healing complications requiring reoperation, (5) nonoperative wound necrosis at 2 or 6 weeks, wound dehiscence at 2 or 6 weeks or superficial infection (CDC criteria), (6) SCAR-Q Symptom Scale, (7) SCAR-Q Appearance Scale

    Time frame: 3 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Sep 2028, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 29, 2024
StartActual
Jan 1, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 31, 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06337292
Lead sponsor
Major Extremity Trauma Research Consortium
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Jan 1, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 12, 2026

Study contacts

Leah Gitajn, MD
Contact
ida.leah.gitajn@hitchcock.org
603-650-5133
I. Leah Gitajn, MD
principal investigator · Dartmouth-Hitchcock Medical Center
Renan Castillor, PhD
principal investigator · Johns Hopkins Bloomberg School of Public Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion